Management of Osteoporosis
Key Points
Key Points
- Patients with non-metastatic cancer may be at risk for osteoporotic fractures due to baseline risks or due to the added risks associated with their cancer therapy.
- Clinicians are advised to assess fracture risk using established tools.
- For those with substantial risk of osteoporotic fracture the clinician should obtain a bone mineral density.
- The bone health of all patients may benefit from optimizing nutrition, exercise and lifestyle.
- When a pharmacologic agent is indicated, bisphosphonates or denosumab, at osteoporosis-indicated dosages, are the preferred interventions.
Assessment
...sessment...
Ris...
...ndation 1.1. It is recommended that...
...ecommendation 1.2. Clinicians should be a...
...ndation 1.3. Clinicians may use a risk assessm...
...reenin...
...mendation 2.1. Patients with non-met...
...n 2.2. Patients with non-metastatic c...
Treatment
Treatmen...
...harmacological Intervention...
...tion 3.1. Clinicians should encour...
...ion 3.2. Clinicians should actively encoura...
...ndation 3.3. Clinicians should acti...
...harmacological Interve...
...3.4. For patients with non-metastatic cance...
...commendation 3.5. Provided T-score and/or r...
...e 1. Algorithm for Maintaining Bone Healt...
...1. Osteoporotic Fracture Risk FactorsHa...
...able 2. Bone Loss Associated with Various Cancer T...
...e 3. Commonly used Bone Modifying Agents...
...imated Drug Costs for Bone Modifying Agents...